A sweeping update on preventing recurrent kidney stones delivers practical advice, clear signals about what probably works and a sharply defined research agenda.

Simple habits, modest dietary shifts and established medicines appear to lower the chance of another painful episode. Major unknowns remain, notably how and when to image people after an initial stone and whether adult strategies apply to children.

Kidney stones are common. They hurt. They recur. About one in four adults will form another stone within five years of their first. For people with prior stones, the risk approaches one in two.

Children may face even higher recurrence. Recurrent stones drive repeated pain, emergency department visits, procedures and occasional serious complications such as infection or kidney injury.

Preventing recurrence matters for patients and for health services. This review, published in Annals of Internal Medicine, organises decades of trials into practical conclusions while signalling where evidence is thin.

“For most adults who have passed a kidney stone, start with hydration and sensible dietary measures: drink enough water to aim for roughly 2 litres of urine production daily where safe, avoid very low dietary calcium, cut excess sodium and moderate animal protein“

Researchers searched major databases and trial registries to December 2025. Eligible studies tested diets, supplements, pharmaceuticals or imaging strategies intended to prevent new or enlarging stones. Trials needed a minimum 12‑month follow‑up and at least 30 participants per group. Non‑English reports and studies from lower human‑development settings were excluded. Results were pooled when trials were comparable. Contemporary tools assessed risk of bias and strength of evidence.

Thirty‑one studies met the criteria: 26 randomised trials and five sizeable observational analyses. Pooled analyses included more than 30,000 people in some comparisons. Most trials enrolled adults with calcium oxalate or calcium phosphate stones. Only three trials involved children; their findings were insufficient. Not a single eligible study evaluated surveillance imaging as a prevention strategy.

Five interventions stood out as likely to reduce recurrence or stone growth in adults. The evidence for each was judged low in strength. Limitations included heterogeneity between trials, modest sample sizes, variable outcome definitions and incomplete adverse‑event reporting.

Still, the pattern across studies points to sensible, low‑cost measures individuals and clinicians can discuss. Always talk to your healthcare providers for medical advice.

Hydration remained a simple, low‑risk starting point. Trials that encouraged people to drink enough to produce about 2 litres of urine daily reported reduced composite recurrence in at least one randomised study. The magnitude of benefit is uncertain. The direction is consistent. Hydration costs little, poses little harm and has other health benefits. It makes sense as a default preventive step unless a clinician advises otherwise.

Dietary advice focused on three elements: maintain normal dietary calcium, reduce sodium and limit excess animal protein. A trial in men with idiopathic hypercalciuria found that a diet with normal to higher calcium, lower animal protein and reduced sodium (eg salt, MSG) lowered recurrence compared with a low‑calcium diet. The physiology is straightforward — dietary calcium binds intestinal oxalate, lowering urinary oxalate, a key driver for many calcium stones. Avoidance of unnecessary calcium restriction, salt reduction and moderating animal protein intake are practical, evidence‑informed steps.

Thiazide diuretics (drug) showed consistent signals of benefit. Trials of hydrochlorothiazide or chlorthalidone versus placebo or no treatment reported fewer composite recurrences over several years. Statistical heterogeneity and varying trial quality led reviewers to downgrade confidence to low, yet the largest recent trial with low risk of bias also found fewer radiographic recurrences. Thiazides remain a common choice, especially when metabolic evaluation shows high urinary calcium.

Citrate therapy (drug), typically potassium citrate, lowered composite recurrence or stone growth in pooled trials. Citrate increases urinary citrate, a natural inhibitor of crystal formation, and raises urine pH, reducing formation of some stones. Lemon juice generated similar but less consistent signals and produced slightly more minor adverse effects in some studies. The overall strength of evidence was low.

Allopurinol (drug) reduced recurrences in trials involving people with hyperuricosuria or mixed risk. It lowers uric acid and may therefore prevent uric acid stones while decreasing uric acid’s promotional role in calcium stones. Evidence quality was judged low.

One exception was acetohydroxamic acid (drug) for infection‑related, struvite stones. The drug reduced stone growth but led to substantially more adverse effects. Evidence for routine prevention is limited; the drug remains a specialist option.

Always consult your healthcare providers before taking any medication or undergoing medical interventions. This is evidence-based general information derived from studies and research and is not a substitute for medical advice.

Across interventions, reported harms were generally modest or poorly reported. Thiazides and allopurinol lacked consistent major safety signals in trials, though many studies offered limited adverse‑event detail. Citrate sometimes caused minor gastrointestinal complaints. Acetohydroxamic acid clearly increased adverse events. Treatment decisions require weighing modest potential benefits against side‑effect risk, polypharmacy and patient preference.

Important questions remain unresolved. No trials tested the frequency or modality of surveillance imaging after a stone. Clinicians must weigh trade‑offs between radiation exposure from CT, lower sensitivity but no radiation with ultrasound, cost, and the risk of incidental findings. Randomised data on imaging strategies would help. Children were nearly absent from the evidence base. Only three paediatric studies met inclusion criteria; their data were insufficient to guide practice. Whether adult prevention strategies translate to children is unknown.

Tailoring therapy to 24‑hour urine results also lacks strong trial support. Two studies compared tailored approaches based on metabolic testing with empirical therapy; pooled evidence did not demonstrate clear superiority for tailored care. Confidence was low to insufficient. Many clinicians nevertheless continue metabolic testing to personalise care. The review reframes the question: testing may inform physiology, but whether it improves patient‑centred outcomes remains unsettled.

Several dietary domains remain understudied. Low‑oxalate diets, soft‑drink reduction, high‑fibre diets and other nutritional tweaks were tested only sparsely, in small inconsistent trials. Strong conclusions cannot be drawn. Dietary counselling remains important. Specific prescriptions beyond calcium maintenance, salt reduction and moderating animal protein lack firm trial backing.

Quality issues limited the certainty of findings. Reviewers used modern risk‑of‑bias tools and structured strength‑of‑evidence methods. Older trials more often showed weaker designs, inconsistent outcome definitions and varied imaging practices. Sample sizes were modest in many studies. Adverse‑event reporting often lacked detail. Several pooled outcomes displayed statistical heterogeneity. Reviewers downgraded many conclusions for imprecision and inconsistency.

What this means in practice is straightforward. For most adults who have passed a kidney stone, start with hydration and sensible dietary measures: drink enough water to aim for roughly 2 litres of urine production daily where safe, avoid very low dietary calcium, cut excess sodium and moderate animal protein.

If stones recur despite these steps, clinicians may reasonably consider thiazide diuretics or potassium citrate after discussing potential benefits and harms. Allopurinol remains an option for selected patients with high uric acid. Metabolic testing can guide personalised decisions, but current trial evidence does not prove that testing improves hard outcomes compared with empirical strategies.

The review sets a clear research agenda. Trials should examine imaging strategies, recruit children, compare drug options head‑to‑head and use standardised, patient‑centred outcomes: symptomatic recurrence, procedures, days off work or school, and quality of life. Behavioural trials to improve adherence to hydration and diet deserve emphasis. Implementation research should test scalable ways to help people follow preventive advice in real life.

For patients and clinicians, the message is pragmatic. Small daily choices matter. Drinking more, keeping dietary calcium adequate and discussing targeted medicines with a clinician offer realistic chances to reduce future painful episodes. Better trials will sharpen guidance.

For now based on evidence from the review, prevention rests on low‑cost, low‑risk measures supported by low‑strength evidence and a cautious but practical clinical approach.